首页> 美国卫生研究院文献>World Journal of Clinical Oncology >Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer
【2h】

Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer

机译:服用多西他赛治疗晚期乳腺癌后发现Charcot-Marie-Tooth遗传性神经病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Charcot-Marie-Tooth (CMT) neuropathy is the most common hereditary cause of neuropathy. Diagnosis is usually not made during the childhood but in adolescence or late adulthood. It is reported in the literature that some neurotoxic chemotherapeutical agents can reveal an asymptomatic CMT IA hereditary neuropathy. To our knowledge, we report here the first case of CMT IA revealed in a 55-year-old woman after the administration of docetaxel/trastuzumab/pertuzumab for metastatic breast cancer. This case stresses again the necessity to obtain a complete personal and familial anamnesis and to perform a neurologic examination before the administration of neurotoxic chemotherapeutical agents to prevent the clinical expression of these hereditary neuropathies.
机译:Charcot-Marie-Tooth(CMT)神经病是神经病的最常见遗传原因。诊断通常不在儿童时期进行,而是在青春期或成年后期进行。据文献报道,某些神经毒性化学治疗剂可显示无症状的CMT IA遗传性神经病。据我们所知,我们在此报告了多西他赛/曲妥珠单抗/培妥珠单抗治疗转移性乳腺癌后在55岁女性中发现的第一例CMT IA。这种情况再次强调了在给予神经毒性化学治疗剂以防止这些遗传性神经病的临床表现之前,必须获得完整的个人和家族性回忆,并进行神经系统检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号